{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:08:56Z","timestamp":1790352536785,"version":"4.1.0"},"reference-count":53,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T00:00:00Z","timestamp":1499472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Tumor-induced bone disease is common among patients with advanced solid cancers, especially those with breast, prostate, and lung malignancies. The tendency of these cancers to metastasize to bone and induce bone destruction is, in part, due to alterations in integrin expression and signaling. Substantial evidence from preclinical studies shows that increased expression of integrin \u03b1v\u03b23 in tumor cells promotes the metastatic and bone-invasive phenotype. Integrin \u03b1v\u03b23 mediates cell adhesion to several extracellular matrix proteins in the bone microenvironment which is necessary for tumor cell colonization as well as the transmission of mechanical signals for tumor progression. This review will discuss the \u03b1v\u03b23 integrin receptor in the context of tumor-induced bone disease. Specifically, the focus will be the role of \u03b1v\u03b23 in modulating cancer metastasis to bone and tumor cell response to the bone microenvironment, including downstream signaling pathways that contribute to tumor-induced osteolysis. A better understanding of integrin dysregulation in cancer is critical to developing new therapeutics for the prevention and treatment of bone metastases.<\/jats:p>","DOI":"10.3390\/cancers9070084","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T11:05:31Z","timestamp":1499684731000},"page":"84","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Integrin \u03b1v\u03b23 Signaling in Tumor-Induced Bone Disease"],"prefix":"10.3390","volume":"9","author":[{"given":"Kristin","family":"Kwakwa","sequence":"first","affiliation":[{"name":"Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN 37212, USA"},{"name":"Vanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"},{"name":"Department of Cancer Biology, Vanderbilt University, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Sterling","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN 37212, USA"},{"name":"Vanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"},{"name":"Department of Cancer Biology, Vanderbilt University, Nashville, TN 37232, USA"},{"name":"Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA"},{"name":"Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2015.02.002","article-title":"HIF targets in bone remodeling and metastatic disease","volume":"150","author":"Johnson","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bone.2010.07.015","article-title":"Advances in the biology of bone metastasis: How the skeleton affects tumor behavior","volume":"48","author":"Sterling","year":"2011","journal-title":"Bone"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11914-016-0315-2","article-title":"The bone microenvironment: A fertile soil for tumor growth","volume":"14","author":"Buenrostro","year":"2016","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrc1528","article-title":"Osteoblasts in prostate cancer metastasis to bone","volume":"5","author":"Logothetis","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I","article-title":"Mechanisms of bone metastasis","volume":"80","author":"Mundy","year":"1997","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bone.2011.02.003","article-title":"Bisphosphonates in oncology","volume":"49","author":"Coleman","year":"2011","journal-title":"Bone"},{"key":"ref_8","first-page":"79","article-title":"The relationship between bone metastasis from human breast cancer and integrin alphavbeta3 expression","volume":"25","author":"Takayama","year":"2005","journal-title":"Anticancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6238","DOI":"10.1038\/sj.onc.1210429","article-title":"Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling","volume":"26","author":"McCabe","year":"2007","journal-title":"Oncogene"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.1158\/0008-5472.CAN-09-0949","article-title":"Beta(3) integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells","volume":"69","author":"Tucci","year":"2009","journal-title":"Cancer Res."},{"key":"ref_11","first-page":"3623","article-title":"High lung-metastatic variant of human osteosarcoma cells, selected by passage of lung metastasis in nude mice, is associated with increased expression of \u03b1(v)\u03b2(3) integrin","volume":"33","author":"Tome","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/jcp.21601","article-title":"Stromal cell-derived factor-1 increase alphavbeta3 integrin expression and invasion in human chondrosarcoma cells","volume":"218","author":"Lai","year":"2009","journal-title":"J. Cell. Physiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.critrevonc.2015.05.018","article-title":"Av\u03b23 integrin: Pathogenetic role in osteotropic tumors","volume":"96","author":"Stucci","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1357-2725(96)00155-0","article-title":"The \u03b1v\u03b23 integrin \u2018vitronectin receptor\u2019","volume":"29","author":"Horton","year":"1997","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.1086652","article-title":"Talin binding to integrin \u03b2 tails: A final common step in integrin activation","volume":"302","author":"Tadokoro","year":"2003","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1083\/jcb.200710196","article-title":"Kindlin-2 (Mig-2): A co-activator of beta3 integrins","volume":"181","author":"Ma","year":"2008","journal-title":"J. Cell. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1126\/science.285.5430.1028","article-title":"Integrin signaling","volume":"285","author":"Giancotti","year":"1999","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Qin, J., Vinogradova, O., and Plow, E.F. (2004). Integrin bidirectional signaling: A molecular view. PLoS Biol., 2.","DOI":"10.1371\/journal.pbio.0020169"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.18632\/oncotarget.6730","article-title":"EGFRvIII\/integrin \u03b23 interaction in hypoxic and vitronectin enriching microenvironment promote GBM progression and metastasis","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1186\/bcr1524","article-title":"Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells","volume":"8","author":"Galliher","year":"2006","journal-title":"Breast Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nrm1490","article-title":"Integrin signalling during tumour progression","volume":"5","author":"Guo","year":"2004","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.bcp.2007.11.017","article-title":"TGF-beta1 increases motility and alphavbeta3 integrin up-regulation via PI3K, Akt and NF-kappaB-dependent pathway in human chondrosarcoma cells","volume":"75","author":"Yeh","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0945-053X(00)00051-2","article-title":"Integrins and signaling in osteoclast function","volume":"19","author":"Duong","year":"2000","journal-title":"Matrix Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1172\/JCI8905","article-title":"Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts","volume":"105","author":"McHugh","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1084\/jem.20060807","article-title":"Integrin signaling is critical for pathological angiogenesis","volume":"203","author":"Mahabeleshwar","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"a006478","DOI":"10.1101\/cshperspect.a006478","article-title":"AlphaV integrins in angiogenesis and cancer","volume":"1","author":"Weis","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/343170a0","article-title":"Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis","volume":"343","author":"Savill","year":"1990","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2010.09.016","article-title":"Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions","volume":"48","author":"Schneider","year":"2011","journal-title":"Bone"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1002\/ijc.28267","article-title":"\u03b1v-Integrin isoform expression in primary human tumors and brain metastases","volume":"133","author":"Vogetseder","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00019606-199606000-00008","article-title":"Integrin \u03b1v\u03b23 expression by bone-residing breast cancer metastases","volume":"5","author":"Liapis","year":"1996","journal-title":"Diagn. Mol. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1096\/fj.01-0911fje","article-title":"Integrin \u03b1v\u03b23 expression confers on tumor cells a greater propensity to metastasize to bone","volume":"16","author":"Peyruchaud","year":"2002","journal-title":"FASEB J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1359\/jbmr.2001.16.11.2027","article-title":"Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions","volume":"16","author":"Peyruchaud","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"R20","DOI":"10.1186\/bcr1398","article-title":"Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone","volume":"8","author":"Sloan","year":"2006","journal-title":"Breast Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/B:CLIN.0000024763.69809.64","article-title":"A small molecule antagonist of the \u03b1v\u03b23 integrin suppresses MDA-MB-435 skeletal metastasis","volume":"21","author":"Harms","year":"2004","journal-title":"Clin. Exp. Metastasis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","article-title":"Breast cancer cells interact with osteoblasts to support osteoclast formation","volume":"140","author":"Thomas","year":"1999","journal-title":"Endocrinology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1158\/0008-5472.CAN-06-4499","article-title":"Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases","volume":"67","author":"Zhao","year":"2007","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/onc.2009.389","article-title":"Runx2 association with progression of prostate cancer in patients: Mechanisms mediating bone osteolysis and osteoblastic metastatic lesions","volume":"29","author":"Akech","year":"2010","journal-title":"Oncogene"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Gupta, A., Cao, W., and Chellaiah, M.A. (2012). Integrin \u03b1v\u03b23 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2\/Smad 5\/receptor activator of NF-\u03baB ligand signaling axis. Mol. Cancer.","DOI":"10.1186\/1476-4598-11-66"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/0008-5472.CAN-10-2993","article-title":"TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling","volume":"71","author":"Johnson","year":"2011","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ccr.2005.08.010","article-title":"Tensional homeostasis and the malignant phenotype","volume":"8","author":"Paszek","year":"2005","journal-title":"Cancer Cell."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","article-title":"Matrix crosslinking forces tumor progression by enhancing integrin signaling","volume":"139","author":"Levental","year":"2009","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12307-011-0078-3","article-title":"Contribution of bone tissue modulus to breast cancer metastasis to bone","volume":"4","author":"Guelcher","year":"2011","journal-title":"Cancer Microenviron."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11914-011-0052-5","article-title":"Bone structural components regulating sites of tumor metastasis","volume":"9","author":"Sterling","year":"2011","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ruppender, N.S., Merkel, A.R., Martin, T.J., Mundy, G.R., Sterling, J.A., and Guelcher, S.A. (2010). Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS One., 5.","DOI":"10.1371\/journal.pone.0015451"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.biomaterials.2015.06.026","article-title":"Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin beta3 and TGF-beta receptor type II","volume":"64","author":"Page","year":"2015","journal-title":"Biomaterials"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1749-6632.2010.05766.x","article-title":"The use of bisphosphonates in cancer treatment","volume":"1218","author":"Coleman","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1158\/1535-7163.MCT-06-0356","article-title":"Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin","volume":"5","author":"Mulgrew","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1158\/1535-7163.MCT-06-0100","article-title":"A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo","volume":"5","author":"Khalili","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1200\/JCO.2008.16.7510","article-title":"Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme","volume":"26","author":"Reardon","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071\u201322072 study): A multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/cncr.24821","article-title":"A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or \u2212dacarbazine in patients with stage IV metastatic melanoma","volume":"116","author":"Hersey","year":"2010","journal-title":"Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10637-015-0320-9","article-title":"A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies","volume":"34","author":"Cirkel","year":"2016","journal-title":"Investig. New Drugs"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/9\/7\/84\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:41:59Z","timestamp":1760208119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/9\/7\/84"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,8]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7]]}},"alternative-id":["cancers9070084"],"URL":"https:\/\/doi.org\/10.3390\/cancers9070084","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,8]]}}}